Accordingly, targeting CSCs and acetyl-CoA biosynthesis using CD133 antibody-conjugated nanoparticles increases tumor-infiltrating CD8<sup>+</sup>CD103<sup>+</sup> T cells and suppresses tumor growth. The gene discussed is CD8A; the disease is neoplasm.